PRTO Insider Trading Activity and SEC Form 4 Filings
PRTO insider trading summary
No open-market insider purchases or sales of Proteon Therapeutics Inc (PRTO) have been reported on SEC Form 4 in the past 12 months.
Latest PRTO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 15, 2017 | Steven Keith Burke | SVP and Chief Medical Officer | Buy | $23K (12,000 @ $1.88) |
| Nov 30, 2017 | Deerfield Management Co | Director | Buy | $193K (110,557 @ $1.75) |
| Nov 30, 2017 | Deerfield International Master Fund, L.P. | 10% Owner | Buy | $193K (110,557 @ $1.75) |
| Nov 30, 2017 | Deerfield Partners, L.P. | 10% Owner | Buy | $193K (110,557 @ $1.75) |
| Nov 30, 2017 | Deerfield Management Co | Director | Sell | $193K (110,557 @ $1.75) |
| Nov 30, 2017 | James E Flynn | Director | Buy | $193K (110,557 @ $1.75) |
| Nov 30, 2017 | Deerfield Mgmt L.P. | 10% Owner | Buy | $193K (110,557 @ $1.75) |
| Nov 30, 2017 | James E Flynn | Director | Sell | $193K (110,557 @ $1.75) |
| Nov 30, 2017 | Deerfield Partners, L.P. | 10% Owner | Sell | $193K (110,557 @ $1.75) |
| Nov 30, 2017 | Deerfield Mgmt L.P. | 10% Owner | Sell | $193K (110,557 @ $1.75) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.